FDA approves Topamax for migraine prevention in adolescents

Today, the U.S. Food and Drug Administration approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. The medication is taken on a daily basis to reduce the frequency of migraine headaches.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391026.htm

Source: Food and Drug Administration - March 28, 2014 Category: American Health Source Type: news

More News: American Health | Food and Drug Administration (FDA) | Headache | Migraine | Topamax